← Back to Search

standard GHST order randomized: clonidine - arginine for Human Growth Hormone Deficiency (DETECT Trial)

Phase 3
Recruiting
Research Sponsored by AEterna Zentaris
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up derived from cmax gh measurements collected in the time frame from 0 to 90 minutes after initial macimorelin ghst (visit 2 (day 0)) and gh adjudication status performed by the adjudication committee after visit 4 (between day 11 and day 58)).
Awards & highlights

DETECT Trial Summary

This trial will study whether the new macimorelin test is safe and works as well as other tests to diagnose growth hormone deficiency (GHD) in children.

Eligible Conditions
  • Human Growth Hormone Deficiency

DETECT Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~derived from cmax gh measurements collected in the time frame from 0 to 90 minutes after initial macimorelin ghst (visit 2 (day 0)) and gh adjudication status performed by the adjudication committee after visit 4 (between day 11 and day 58)).
This trial's timeline: 3 weeks for screening, Varies for treatment, and derived from cmax gh measurements collected in the time frame from 0 to 90 minutes after initial macimorelin ghst (visit 2 (day 0)) and gh adjudication status performed by the adjudication committee after visit 4 (between day 11 and day 58)). for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Area under the Receiver Operator Characteristic curve (ROC AUC) based on GH concentration during GHST following macimorelin administration
Secondary outcome measures
Overall agreement between the outcome of the macimorelin GHST and the combined outcome from the 2 standard GHSTs
Sensitivity for the macimorelin GHST
Specificity for the macimorelin GHST

DETECT Trial Design

2Treatment groups
Active Control
Group I: standard GHST order randomized: clonidine - arginineActive Control3 Interventions
At V2, all subjects will perform the macimorelin GHST and will be randomized 1:1 to the order of the clonidine and arginine GHSTs at V3 and V4. In this arm, those subjects will be presented which will have been randomized to the clonidine GHST at V3 and to the arginine GHST at V4. At V5 all subjects will perform the macimorelin GHST.
Group II: standard GHST order randomized: arginine - clonidineActive Control3 Interventions
At visit 2 (V2), all subjects will perform the macimorelin GHST and will be randomized 1:1 to the order of the clonidine and arginine GHSTs at visit 3 (V3) and visit 4 (V4). In this arm, those subjects will be presented which will have been randomized to the arginine GHST at V3 and the clonidine GHST at V4. At visit 5 (V5) all subjects will perform the macimorelin GHST.

Find a Location

Who is running the clinical trial?

Novo Nordisk A/SIndustry Sponsor
1,513 Previous Clinical Trials
2,414,929 Total Patients Enrolled
6 Trials studying Human Growth Hormone Deficiency
170 Patients Enrolled for Human Growth Hormone Deficiency
AEterna ZentarisLead Sponsor
41 Previous Clinical Trials
5,167 Total Patients Enrolled
Nicola K Ammer, MDStudy DirectorAEterna Zentaris

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any other research papers which compare the results of the standard GHST order of arginine and clonidine?

"The randomized standard order of GHST: arginine - clonidine was first trialled in 2021 at Azienda Ospedaliero-Universitaria Anna Meyer. So far, there have been 59 completed studies with 1 currently active trial. Many of these studies are conducted in Greenwood Village, Colorado."

Answered by AI

Is the combination of arginine and clonidine in GHST form safe for patients?

"Standard GHST order randomized: arginine - clonidine has received a safety score of 3 from our team at Power. This is because it is a Phase 3 trial, which means that there is both efficacy and safety data from multiple rounds of testing."

Answered by AI

Does age limit eligibility for participation in this trial?

"Children that are above the age of 2 and under the age of 17 are eligible for this clinical trial."

Answered by AI
~29 spots leftby Apr 2025